


PRELIMINARY PROGRAM

29th International Conference



**Advances in the Applications of Monoclonal Antibodies in
Clinical Oncology and Symposium on Cancer Stem Cells**

Santa Marina Hotel, Mykonos, Greece


25- 27, June 2012

Information and registration:

www.cancerconferences.org

agamemnon@epenetos.com

WE ARE GRATEFUL TO OUR SPONSORS FOR THEIR SUPPORT



Trojantec

Monday 25th June 2012

07.30-8.55 *Registration*

8.55- 9.00 Agamemnon Epenetos: Welcome

SESSION 1 Chairman: Kerry Chester

9.05- 9.20 Christophe Caux, Cancer Research Center of Lyon, France

Therapeutic targeting of tumor cells and their immune environment

9.20- 9.40 Meher Majety, Roche, Germany.

Fibroblasts induce proliferation and influence therapeutic response of cancer cells in a novel 3D co-culture model

9.40-10.00 Paul Parren, Genmab, Holland

Daratumumab, a human CD38 antibody with broad-spectrum killing activity

10.00-10.20 Alexander Lifke / Johannes Sam, Roche, Germany

A mouse model which has a human immune system

10.20- 11.00 Coffee break /poster review

SESSION 2 Chairman: Klaus Bosslet

11.00-11.20 Kerry Chester, UCL, UK

Developing Antibody -Targeted Nanoparticles for Cancer Therapy

11.20-11.40 Eugene Zhukovsky, Affimed, Germany

RECRUIT-TandAbs: a versatile bispecific platform designed for immune therapy of cancer

11.40 -12.00 Katharina Wartha or Carola Ries, Roche, Germany

Targeting tumor associated macrophages with a humanized anti-CSF1R antibody: A new approach for anti-tumor therapy.

12.00-12.20 Raum Tobias, Micromet, Germany

BiTE Antibodies: Recruiting T Cells for Cancer Therapy

13.00- 14.00 *Lunch break*

14.00- 15.00 *Open Air Workshop: Klaus Bosslet & Raum Tobias*

Can we activate the immune system for a beneficial effect?

SESSION 3 Chairman: Surinder Sharma

17.00- 17.20 Steven Rust, MedImmune, UK

Antibody Phenotypic Screening for Early Biomarker Discovery and Validation

17.20-17.40 Teodor Aastrup, Attana, USA

A novel tool for characterization of molecular interactions on cell surfaces

17.40- 18.00 Tariq Ghayur, Abbott, USA

Exploiting the flexibility of dual - variable - domain (DVD) - Ig format to reveal novel receptor biology

18.00-18.20 Gregory P. Adams, Fox Chase Cancer Center , Philadelphia, USA

Anti-Mullerian Inhibiting Substance Type II Receptor Antibodies for Ovarian Cancer Therapy

20.00- 22.00

Welcome Reception Cocktail

Tuesday 26th June 2012

SESSION 4 Chairman: Mahendra Deonarain

9.00-9.20 David King AnaptysBio, San Diego, USA

Generating improved antibody therapeutics through somatic hypermutation in vitro

09.20-09.40 Majid Mehtali, Vivalis, France

High throughput single cell screening of human primary B lymphocytes for the discovery of rare therapeutic monoclonal antibodies

09.40-10.00 Lars Stockl, Glycotope, Germany

Production of glycol-optimized antibodies for cancer treatment

10.00-10.20 Cecile Geuijen, Merus, The Netherlands

Targeting multiple epitopes on tumor cells using the single light chain antibody format

10.20- 11.00 Coffee break /poster review

SESSION 5 Chairman: Aleksandra Fillipovic

11.00-11.20 Michael Stumpp Molecular Partners, Switzerland

Recent progress with DARPins in oncology

11.20-11.40 Laurent Audoly , Pieris, Germany

Differentiated next generation small biologicals in oncology - Anticalins case studies

11.40-12.00 Bob Lutz, Immunogen,USA

Development of Antibody-Drug Conjugates for the Treatment of Cancer

12.00-12.20 Dennis Benjamin, Seattle Genetics, USA

Empowering Antibodies for Cancer Therapy

12.20-12.40 Victor Goldmacher, Immunogen, USA

IMGN853, an anti-Folate Receptor 1 ADC with novel linker that counters multi-drug resistance

13.00- 14.00 Lunch break

14.00- 15.00 Open Air Workshop: Dennis Benjamin and Laurent Audoly

Loaded antibodies .

SESSION 6 Chairman: Christina Kousparou

17.00-17.20 Stefan Weigand, Roche ,Germany

Novel anti CD44 antibody with unique mode of action

17.20-17.40 Katherine A. Vallis, University of Oxford UK

Radioimmunoconjugates for intra-nuclear targeting

17.40-18.00 Anna Wu LA , USA

Engineered antibody fragments for immunoPET detection of cancer

20.00-untillate
Conference Dinner

Wednesday 27th June 2012

SESSION 7 Chairman: Katherine Vallis

09.00-09.20 Ferdinand Bach, Oncoscience, Germany

Preclinical and clinical development of nimotuzumab

09.20-09.40 Lois Lampson, Harvard University, USA

Monoclonal antibody treatment for brain tumors - despite the blood-brain barrier

09.40-10.00 Thomas Valerius, Kiel University, Germany

Approaches to enhance the efficacy of epidermal growth factor receptor (EGFR)- directed antibodies

10.0-10.20 Anna Hultberg, arGEN-X, Belgium

New Insights into Modulation of c-Met Function in Cancer through the SIMPLE Antibody™ Platform

10.20-11.00 Coffee break/ poster review

**SESSION 8 CANCER STEM CELL SYMPOSIUM:
Chairman: Agamemnon Epenetos**

11.00-11.20 Christina Gewinner, UCL, UK

**Loss of Inositol Polyphosphate 4-Phosphatase type II in ovarian cancer patients-
Implication for PARP inhibition**

11.20- 11.40 Aleksandra Filipovic, ICL, UK

**Biological and clinical implications of nicastrin expression and function in cancer stem
cells.**

11.40-12.00 Christina Kousparou, Trojantec Cyprus and UK

Creating an anti-cancer stem cell Trojan Horse

12.00- 12.20 Ronan O'Hagan, Merck, USA

Antibodies against Notch receptors

12.20- 12.40 Silvia Colucci, Imperial College London, Trojantec, UK and Cyprus

Intranuclear-targeting of Cancer Stem Cells at the Mastermind level

12.40-13.00 Sergej Kiprijanov, Affitech, Norway

A therapeutic Anti-VEGF Antibody

Agamemnon Epenetos
Farewell

POSTER PRESENTATIONS

**These will be displayed in the Hall area during the
whole period of the conference**

Information and registration:

www.cancerconferences.org

agamemnon@epenetos.com

